Loading…
← CockpitCompetitor Analysis › EWTX Edgewise Therapeutics, Inc.Open in the cockpit ↗

Edgewise Therapeutics, Inc.EWTXCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops precision medicines for genetically defined muscle diseases including Duchenne muscular dystrophy and cardiomyopathies.

Momentum strong 75
Mkt cap
$4.53B
US dollars, full cap
Free float
75%
of shares outstanding
$/day
$68.7M
20-day average traded
P/B
2.77×
price to book
ROE
92.2%
delivered
Implied ROE
14.2%
what the price asks
Next earnings
99 days
25 Feb 2027
Close · USD$41.37
1D-1.6%
1W-13.0%
1M+4.1%
3M-4.4%
6M+26.1%
YTD+66.7%
1Y+85.8%
ATR %6.7%
Beta1.10
52w lowhigh15.2% off high

What Edgewise Therapeutics does

Develops precision medicines for genetically defined muscle diseases including Duchenne muscular dystrophy and cardiomyopathies.

Has no approved product and so no sales; trial spending is funded by raising money from investors and from cash on hand. Any future income depends on regulators approving one of its medicines, which would then be sold to a small group of specialist doctors.

Products and services

  • Sevasemten (Duchenne/Becker muscular dystrophy)
  • EDG-7500 (hypertrophic cardiomyopathy)

Customers

  • Neuromuscular disease specialists
  • Cardiologists (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Muscle-disease precision medicine

What could go right

  • Pivotal trial data readouts
  • Cardiomyopathy market expansion

What could go wrong

  • Clinical trial failure risk
  • Competitive muscular dystrophy treatment landscape

Moat: none (IP / patents). Clinical-stage biotech with novel muscle-targeted mechanisms but no approved products yet.

Headquarters: Boulder, Colorado, US · Founded: 2017 · Employees: 146

Named competitors

Edgewise Therapeutics at a glance

Size Edgewise Therapeutics (EWTX) is a United States Health Care company (Biotechnology) with a market value of $4.53B, the 1249th largest of 3,085 United States companies the cockpit tracks. Shares closed at $41.37 on 18 Nov 2026.

Performance Over six months the shares gained 26.1%, against -0.3% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.

Valuation It trades at 2.77× book value against a peer median of 3.58× (10th cheapest of 21).

Price implies The share price implies a return on equity of about 14.2%; Edgewise Therapeutics delivers 92.1%, so the price asks less than the business earns today.

Short interest Short interest is 11.6% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026EWTX 127Peer median 101
Six months, rebased to 100: Edgewise Therapeutics against the median of its 20 peers (local-currency closes).

Edgewise Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$2.35M-$2.27M-$2.29M-$1.73M-$538,000
EBITDA-$216M-$189M-$157M-$113M-$71.1M
Net income$1.01B-$168M-$134M-$100M-$67.6M
Free cash flow-$202M-$144M-$110M-$97.7M-$58.2M
Capital expenditure$382,000$256,000$1.31M$5.75M$5.55M
Total debt$3.38M$3.99M$4.74M$5.41M$4.41M

Quarterly statements and history in the cockpit →

Edgewise Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%-20%0%000661002252ADPTDNTH33471530COGT6033926696CRSP300122ANTHEMTNGX6127CAIRLAYABCLIRONSRRK600161EWTX6-month return →1-month return →
Up and to the right = strong over both horizons. Edgewise Therapeutics is the large dot.

Fundamentals: return on equity against price-to-book

-100%-50%0%50%00×100×200×000661002252ADPTDNTH1530COGT6033926696CRSP300122ANTHEMCAIRLAYSRRK600161EWTXReturn on equity →Price / book →
A bank or insurer earning more on its equity usually trades at a higher multiple of book; points far above the trend are priced for more. Edgewise Therapeutics is the large dot.

Capital: ROE delivered against the ROE the price implies

-100%0%100%200%-100%0%100%200%000661002252ADPTDNTH1530COGT603392300122ANTHEMTNGXCAIRLAYSRRKEWTXROE delivered →ROE the price implies →
Above the diagonal = the price asks for a higher return on equity than the business earns today. Edgewise Therapeutics is the large dot.

Edgewise Therapeutics competitors and peer comparison

Head to head with its named competitors (EWTX vs SRPT vs CYTK vs BBIO)
CompanyMarket cap6M returnRevenue growthROEPrice / bookImplied ROE
Edgewise Therapeutics EWTX$4.53B+26%n/a92%2.77×14.2%
Sarepta Therapeutics SRPT$1.56B-15%-19%-8%1.02×7.4%
Cytokinetics CYTK$7.15B-35%+30%n/an/an/a
BridgeBio Pharma BBIO$15.2B+14%+167%n/an/an/a

How Edgewise Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Edgewise Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureEWTXPeer medianRank in peer set
1-month return+4.1%-5.3%7th highest of 21
6-month return+26.1%-0.3%5th highest of 21
Return on equity92.2%-18.6%highest of 21
Price / book2.77×3.58×10th cheapest of 21
Trailing P/E5.0×30.6×2nd cheapest of 7
ROE the price implies14.2%35.8%6th least demanding of 21
ROE delivered92.1%-18.6%highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthROEPrice / bookImplied ROEDelivered ROE
Edgewise Therapeutics EWTXUnited States$4.53B+26%n/a92%2.77×14.2%92.1%
Changchun High-Tech Industry (Group) 000661.SZChina$4.52B-13%-18%-2%1.32×13.5%-1.9%
Shanghai RAAS Blood Products 002252.SZChina$4.57B-15%-22%3%0.94×3.8%3.3%
Adaptive Biotechnologies ADPTUnited States$4.61B+104%+18%-37%26.09×341.6%-37.1%
Dianthus Therapeutics DNTHUnited States$4.73B-5%-12%-23%3.81×39.0%-22.6%
Hangzhou Tigermed Consulting 3347.HKHong Kong$4.75B0%+22%-2%1.18×13.9%-2.0%
3SBio 1530.HKHong Kong$4.28B-31%+102%37%1.04×9.8%36.7%
Cogent Biosciences COGTUnited States$4.84B-16%n/a-100%10.72×44.4%-99.6%
Beijing Wantai Biological Pharmacy Enterprise 603392.SSChina$4.20B-43%+8%-4%2.41×18.0%-3.8%
Lin BioScience 6696.TWOTaiwan$3.98B+305%n/a-24%12.29×40.2%-24.0%
CRISPR Therapeutics CRSPUnited States$3.90B-17%-34%-26%2.36×30.5%-25.6%
Chongqing Zhifei Biological Products 300122.SZChina$5.28B-1%-28%-64%2.32×24.5%-63.8%
Anthem Biosciences ANTHEM.NSIndia$5.51B+16%-1%20%15.70×125.3%20.4%
Tango Therapeutics TNGXUnited States$3.71B+4%-100%-36%3.78×34.6%-36.5%
JOINN Laboratories (China) 6127.HKHong Kong$3.70B+6%+17%13%1.31×16.7%13.3%
Caris Life Sciences CAIUnited States$5.59B+24%+61%17%8.74×51.8%17.2%
Relay Therapeutics RLAYUnited States$3.65B+27%+24%-41%4.42×50.9%-41.2%
AbCellera Biologics ABCLUnited States$3.60B+141%+92%-15%3.38×37.0%-14.6%
Disc Medicine IRONUnited States$3.55B+16%n/a-41%4.98×37.2%-41.3%
Scholar Rock SRRKUnited States$5.86B-1%n/a-200%34.70×212.2%-200.0%
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%6%1.95×7.4%6.0%

Questions

Who are Edgewise Therapeutics's main competitors?
Named competitors: Sarepta Therapeutics (SRPT), PepGen (private or unlisted), Cytokinetics (CYTK), BridgeBio Pharma (BBIO). The cockpit's measured peer set (industry) also includes Changchun High-Tech Industry (Group) (000661.SZ), Shanghai RAAS Blood Products (002252.SZ), Adaptive Biotechnologies (ADPT), Dianthus Therapeutics (DNTH), Hangzhou Tigermed Consulting (3347.HK), 3SBio (1530.HK).
Is Edgewise Therapeutics expensive compared with its peers?
On price / book it trades at 2.77× against a peer median of 3.58×, 10th cheapest of 21 in its peer set. The share price implies a return on equity of about 14.2%; Edgewise Therapeutics delivers 92.1%, so the price asks less than the business earns today.
How has Edgewise Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +26.1% against -0.3% for the median peer; over one year +85.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.